EGFR and nasopharyngeal carcinoma: After promising phase 1 data, the bispecific EGFR-HER3-targeted ADC, BL-B01D1, is currently being studied in a phase 3 trial, compared with chemotherapy, for patients with previously treated r/m NPC who progressed on PD-1 inhibitor therapy (NCT06118333, Table 3) [58].